Thumbs Up/Thumbs Down: Novartis's retreat leaves plenty of casualties; Biogen orchestrates a shameful media show, and more
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.
…
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
